These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25268703)

  • 1. Impact of α-targeted radiation therapy on gene expression in a pre-clinical model for disseminated peritoneal disease when combined with paclitaxel.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2014; 9(9):e108511. PubMed ID: 25268703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    PLoS One; 2016; 11(7):e0159904. PubMed ID: 27467592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression profiling upon (212) Pb-TCMC-trastuzumab treatment in the LS-174T i.p. xenograft model.
    Yong KJ; Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    Cancer Med; 2013 Oct; 2(5):646-53. PubMed ID: 24403230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Mol Cancer Ther; 2012 Mar; 11(3):639-48. PubMed ID: 22238365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Br J Cancer; 2013 May; 108(10):2013-20. PubMed ID: 23632482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1119-26. PubMed ID: 23200172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Cell Killing Response from Low Linear Energy Transfer (LET) Radiation Originating from (177)Lu Radioimmunotherapy Targeting Disseminated Intraperitoneal Tumor Xenografts.
    Yong KJ; Milenic DE; Baidoo KE; Brechbiel MW
    Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Abdulla A; Flynn J; Brechbiel MW
    Clin Cancer Res; 2007 Mar; 13(6):1926-35. PubMed ID: 17363549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multimodality therapy: potentiation of high linear energy transfer radiation with paclitaxel for the treatment of disseminated peritoneal disease.
    Milenic DE; Garmestani K; Brady ED; Baidoo KE; Albert PS; Wong KJ; Flynn J; Brechbiel MW
    Clin Cancer Res; 2008 Aug; 14(16):5108-15. PubMed ID: 18698028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.
    Milenic DE; Baidoo KE; Shih JH; Wong KJ; Brechbiel MW
    Cancer Biother Radiopharm; 2013; 28(6):441-9. PubMed ID: 23758610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
    Milenic DE; Baidoo KE; Kim YS; Brechbiel MW
    MAbs; 2015; 7(1):255-64. PubMed ID: 25587678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
    Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
    MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
    Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthermia Synergizes with Chemotherapy by Inhibiting PARP1-Dependent DNA Replication Arrest.
    Schaaf L; Schwab M; Ulmer C; Heine S; Mürdter TE; Schmid JO; Sauer G; Aulitzky WE; van der Kuip H
    Cancer Res; 2016 May; 76(10):2868-75. PubMed ID: 27013194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
    Milenic DE; Garmestani K; Brady ED; Albert PS; Ma D; Abdulla A; Brechbiel MW
    Cancer Biother Radiopharm; 2005 Oct; 20(5):557-68. PubMed ID: 16248771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.
    Milenic DE; Brady ED; Garmestani K; Albert PS; Abdulla A; Brechbiel MW
    Cancer; 2010 Feb; 116(4 Suppl):1059-66. PubMed ID: 20127951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The concerted roles of FANCM and Rad52 in the protection of common fragile sites.
    Wang H; Li S; Oaks J; Ren J; Li L; Wu X
    Nat Commun; 2018 Jul; 9(1):2791. PubMed ID: 30022024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.
    Wang S; Huang J; Lyu H; Cai B; Yang X; Li F; Tan J; Edgerton SM; Thor AD; Lee CK; Liu B
    Breast Cancer Res; 2013; 15(5):R101. PubMed ID: 24168763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.